Program
futibatinib
Also written as “Futibatinib”, “TAS-120” and “futibatinib, fulvestrant”.
Its studies are mostly in Cholangiocarcinoma · Neoplasm Metastasis · Adenocarcinoma Of Esophagus · Biliary Tract Neoplasms · Breast Neoplasms, led by Otsuka.
Furthest: phase 3, since Sep 16, 201910 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 104 open or running | phase 3since Sep 16, 2019 | Jan 23, 2014 | Dec 2026phase 2 · NCT05727176 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 23, 2014First study: phase 2 study in CholangiocarcinomaFirst studyNCT02052778 · 407 enrolled · United States, Australia, Canada and more
- Jun 24, 2019Phase 2 study in Breast NeoplasmsNCT04024436 · 64 enrolled · United States, Canada, France and more
- Sep 16, 2019Phase 3 study in Advanced CholangiocarcinomaNCT04093362 · 10 enrolled · United States, Argentina, Australia and more
- Dec 3, 2019Phase 2 study in Neoplasm MetastasisNCT04189445 · 115 enrolled · United States, Belgium, France and more
- Oct 15, 2020Phase 2 study in Advanced and Metastatic Urothelial CancerNCT04601857 · 43 enrolled · United States, France, Spain
- Jul 6, 2021Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04965818 · 38 enrolled · United States
- Jan 23, 2023Phase 2 study in CholangiocarcinomaNCT05727176 · 120 planned · United States, Argentina, Australia and more
- Jul 6, 2023Phase 2 study in Adenocarcinoma Of EsophagusNCT05945823 · 53 enrolled · United States, France, Germany and more
- Jun 28, 2024Phase 3 study in Neoplasm MetastasisNCT06506955 · 15 enrolled · United States, France, South Korea and more
- Jul 3, 2026Phase 3 study in Biliary Tract NeoplasmsNCT07710885 · 784 planned · Australia, Japan, South Korea and more
Ahead
- Dec 2026Primary completion: phase 2 study in CholangiocarcinomaNCT05727176
- Apr 2027Primary completion: phase 3 study in Neoplasm MetastasisNCT06506955
- Apr 30, 2030Primary completion: phase 3 study in Biliary Tract NeoplasmsNCT07710885
TargetBeta
“Fibroblast growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| infigratinibrule | BridgeBio | phase 3 | 17 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07710885Biliary Tract Neoplasms · Australia, Japan, South Korea and more | 3 | Recruiting | Apr 30, 2030 | 784 |
| NCT06506955Neoplasm Metastasis · United States, France, South Korea and more | 3 | Active, not recruiting | Apr 2027 | 15 |
| NCT05945823Adenocarcinoma Of Esophagus · United States, France, Germany and more | 2 | Active, not recruiting | Oct 1, 2026 | 53 |
| NCT05727176Cholangiocarcinoma · United States, Argentina, Australia and more | 2 | Recruiting | Dec 2026 | 120 |
| NCT04965818Carcinoma, Non-Small-Cell Lung · United States | 1 | Terminated | Jun 11, 2023 | 38 |
| NCT04601857Advanced and Metastatic Urothelial Cancer · United States, France, Spain | 2 | Terminated | Mar 8, 2024 | 43 |
| NCT04189445Neoplasm Metastasis · United States, Belgium, France and more | 2 | Terminated | Nov 11, 2024 | 115 |
| NCT04093362Advanced Cholangiocarcinoma · United States, Argentina, Australia and more | 3 | Terminated | Apr 22, 2024 | 10 |
| NCT04024436Breast Neoplasms · United States, Canada, France and more | 2 | Terminated | May 31, 2023 | 64 |
| NCT02052778Cholangiocarcinoma · United States, Australia, Canada and more | 2 | Completed | Oct 1, 2020 | 407 |
How it is read
Names in the registry
- “Futibatinib”, 7 entries
- “TAS-120”, 1 entry
- “futibatinib”, 1 entry
- “futibatinib, fulvestrant”, 1 entry
- “Futibatinib plus Fulvestrant”, 1 entry
Conditions, from the studies’ own filings
- Cholangiocarcinoma, 3 studies
- Neoplasm Metastasis, 2 studies
- Adenocarcinoma Of Esophagus, 1 study
- Biliary Tract Neoplasms, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.